Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC from histology of kidney Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Naveen Vasudev talks to ecancer about the PRISM study, a randomised phase II study looking at nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma.nnHe begins by talking about the background to the study, touching on results that have been seen from prior studies in kidney cancer and melanoma that clearly there is a relationship between the dose of IPI and its associated toxicity, but the frequency in which IPI
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)